Abstract

Ovarian cancer is still an unsolved therapeutical problem in gynaecology. Inspite the occasional use of therapies exercising a great strain, the resulting overall 5-year survival is hardly unchanged. Genetic factors are probably involved in the origin of the cancer. Vaginal sonography and CA-125 screening determination have not yet been routinely established. Primary cytoreductive surgery is meanwhile a cornerstone of the treatment of advanced stages of ovarian cancer. In contrast, secondary cytoreduction is restricted to individual cases. For the second line-chemotherapy taxol was introduced. This substance has a new principle of efficacy and can obtain response rates in cisplatinum-nonresponders. An efficient treatment of ovarian cancer can only be carried out by a systemic approach involving immunological and genetic methods.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.